Since September, all newborns in Dalarna have been offered a preventive treatment against RSV in the form of a shot of antibodies that reduces the risk of serious RSV infections during the first six months of life. This initiative has shown promising results, as only one child in the 0-6 month age range has been treated for a serious RSV infection this winter, and that child was visiting from outside the region and did not receive the new immunization at birth.

In previous seasons, a handful of children aged 0 to 6 months have required treatment for serious RSV infections annually, indicating that the new preventive measure could significantly impact public health. Dr. Peter Erensjö, the head of pediatric medicine in Region Dalarna, notes that the numbers can vary considerably; some seasons have seen a far greater incidence of RSV infections among young children.

There is also a growing desire for a vaccine for pregnant women to further enhance immunity in newborns without the need for early injections. Studies suggest that administering antibodies at birth can provide similar protection to those infants whose mothers have been vaccinated prior to delivery, pointing to an evolving landscape in the fight against RSV and the potential for further advancements in maternal and infant healthcare.